Highlights VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-15 pm EDT			5-day change	1st Jan Change
2.76 ^USD	-4.50%		+1.47%	+18.45%

May. 09	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	MT
May. 09	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	May. 09	MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	May. 06	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	Feb. 29	MT
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	Jan. 10	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	Nov. 13	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	23-10-30	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $135,000	23-08-14	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $99,000	23-05-11	MT
VYNE Therapeutics Inc. Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions	23-05-01	CI
VYNE Therapeutics Inc. Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis	23-04-19	CI
VYNE Therapeutics Inc. Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1A Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain Bet Inhibitor Vyn201	23-03-30	CI
VYNE THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-14	AQ
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-09	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Highlights

Filters